



Universiteit
Leiden
The Netherlands

Recognition and management of persistent postpartum haemorrhage: Time to take timing seriously

Henriquez, D.D.C.A.

Citation

Henriquez, D. D. C. A. (2020, December 1). *Recognition and management of persistent postpartum haemorrhage: Time to take timing seriously*. Retrieved from <https://hdl.handle.net/1887/138245>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/138245>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/138245> holds various files of this Leiden University dissertation.

Author: Henriquez, D.D.C.A.

Title: Recognition and management of persistent postpartum haemorrhage: Time to take timing seriously

Issue date: 2020-12-01

3

Management of postpartum haemorrhage: how to improve maternal outcomes?

Dacia D.C.A. Henriquez, Kitty W.M. Bloemenkamp, Johanna G. van der Bom

Journal of Thrombosis and Haemostasis, 16: 1523–1534



Summary

Postpartum hemorrhage is the leading cause of maternal mortality and severe morbidity. Despite efforts to improve maternal outcomes, management of postpartum hemorrhage still faces at least four challenges, discussed in this review. First, current definitions for severe postpartum hemorrhage hamper early identification of women with high risk of adverse outcome. Adaptations to the definitions and the use of clinical tools such as shock index and early warning systems may facilitate this early identification. Second, surgical and radiological interventions to prevent hysterectomy are not always successful. More knowledge on the influence of patient and bleeding characteristics on the success rates of these interventions is necessary. Scarce data suggest that early timing of intra-uterine balloon tamponade may improve maternal outcomes, whereas early timing of arterial embolization seems to be unrelated to maternal outcomes. Third, fluid resuscitation with crystalloids and colloids is unavoidable in the early phases of postpartum hemorrhage, but may result in dilutional coagulopathy. Effects of different volumes of clear fluids on the occurrence of dilutional coagulopathy and maternal outcomes is unknown. Fourth, a better understanding of diagnosis and correction of coagulopathy during postpartum hemorrhage is needed. Low plasma fibrinogen levels at the start of postpartum hemorrhage predict progression to severe hemorrhage, but standard coagulation screens are time-consuming. A solution may be point-of-care coagulation testing, however, clinical usefulness during postpartum hemorrhage has not been demonstrated. To date, early administration of tranexamic acid is the only hemostatic intervention that was proven to improve outcomes in women with postpartum hemorrhage.

Keywords: blood transfusion, hemostasis, point-of-care testing, postpartum hemorrhage, resuscitation

Introduction

In 2014, the WHO concluded from a systematic analysis that postpartum hemorrhage accounts for almost one fifth of maternal deaths worldwide, ranging from 8% of all maternal deaths in developed regions to 29% in Eastern Asia and 32% in Northern Africa ¹. Incidences of postpartum hemorrhage continue to increase, even in high-resource settings ²⁻⁷. Depending on the definition used, the incidence of postpartum hemorrhage ranges from 3 to 8% of all deliveries ^{2-4,6}.

Main causes of postpartum hemorrhage are uterine atony and placental problems including retained placenta and abnormally invasive placenta. Even though numerous risk factors for postpartum hemorrhage have been identified, it is still an unpredictable obstetric emergency. As a consequence, every woman is considered at risk of developing postpartum hemorrhage following delivery⁸.

Quality improvement tools such as triggers, bundles, checklists and protocols in women with postpartum hemorrhage may improve maternal mortality and severe maternal morbidity ⁹⁻¹¹. Introduction of these tools was reported to reduce the use of blood products and improve patient safety in women with postpartum hemorrhage ¹¹. However, there may be room for improvement in the separate components of these tools. Consequently, optimization of the management of ongoing postpartum hemorrhage still faces numerous challenges

In this article, we review the literature on these controversial issues. We discuss 1) adaptations to postpartum hemorrhage definitions and clinical tools for early identification of women at high risk of adverse outcome, 2) timing of obstetric interventions to stop bleeding, 3) timing of switch from volume resuscitation with clear fluids to transfusion of packed red blood cells and 4) timing of hemostatic interventions to correct coagulopathy in women with severe postpartum hemorrhage.

Improving maternal outcomes: timely recognition of patients with severe postpartum hemorrhage

Definition of severe postpartum hemorrhage

Currently, postpartum hemorrhage and its severity are defined by estimated blood loss within 24 hours following delivery ¹². Cut-off values of 500 and 1000 mL are used for defining postpartum hemorrhage, with the latter mostly used in high-resource settings ¹³. However, these cut-off values are relatively poor in identifying women with high risk of severe maternal morbidity and mortality, as only a small proportion of women that reach these cut-off values of blood loss progress to hemorrhage leading to hysterectomy or maternal death.

In a recent Delphi study performed by the International Network of Obstetric Surveillance Systems (INOSS), consensus definitions of several conditions of severe maternal morbidities were developed. The proposed definition for severe primary postpartum hemorrhage was blood loss exceeding 2000 mL and/or the need of transfusion of at least four units of packed red blood cells ¹⁴. This definition enables selection of women with a higher risk of adverse maternal outcome than women with blood loss exceeding 500 or 1000 mL, while facilitating international comparisons of incidences of severe maternal morbidity and mortality as a result of postpartum hemorrhage. In practice, however, this definition excludes the possibility of early identification of women at high risk of adverse maternal outcome, as this definition reflects an intermediary or even end stage of hemorrhage.

Qualitative studies among experienced birth attendants show that severity of hemorrhage not only depends on volume of blood loss, but also on rate of bleeding and physiological response to bleeding ¹⁵. In recognition of these determinants, several guidelines incorporated clinical signs of shock to express physiological response to bleeding in the definition of severe postpartum hemorrhage ^{16,17}. In addition, an international expert panel proposed to add *response to treatment* as a determinant of severity to the definition of postpartum hemorrhage, and suggested defining severe postpartum hemorrhage as persistent (ongoing) hemorrhage >1000 mL within 24 hours following birth that continues despite the use of initial measures to stop bleeding ⁸. Adding *refractoriness to initial measures* to the definition of postpartum hemorrhage has the potential advantage of early identification of women at high risk of adverse maternal outcome by considering women as having a severe hemorrhage

as soon as initial uterotonic treatment fails to stop hemorrhage. Whether or not this adaptation will improve maternal outcomes might become clear in the near future, as this extension has already been implemented in a national guideline (figure 1)¹⁸.

Clinical tools for early recognition of women with severe postpartum hemorrhage

Cardiac output increases during pregnancy due to a physiologic increase in heart rate and blood volume and blood pressure decreases due to lower systemic vascular resistance^{19,20}. Cardiac output further increases during labor and delivery, because of a higher preload caused by uterine contractions. After delivery, preload further increases as a result of relief of inferior vena cava compression by the gravid uterus and the return of uterine blood to maternal circulation. As a result, early recognition of a deterioration in clinical condition in women with postpartum hemorrhage is difficult²¹.

This early detection of deterioration in clinical condition has gained a lot of interest over the past decades, both in the pregnant and non-pregnant patients. Recent studies examined whether the *shock index* and *early warning systems* can be used to monitor women with postpartum hemorrhage. The *shock index* is the ratio of heart rate to systolic blood pressure. In the non-pregnant population a shock index >1.0 , thus a higher heart rate than systolic blood pressure measured at least once in the observation period, has been associated with morbidity and mortality in critically ill patients suffering trauma, sepsis and after surgery²²⁻²⁵. A study among 8874 women without postpartum hemorrhage reported a range of 0.5 to 1.1 for the shock index immediately following delivery²⁶. Another study among 233 women with postpartum hemorrhage with blood loss exceeding 1500 mL concluded that a shock index ≥ 1.7 was a predictor of intensive care unit admission, invasive surgical procedures and transfusion of ≥ 4 units of packed red blood cells, with respective area under the curves 0.75 (95% confidence interval 0.63-0.87), 0.62 (0.45-0.79) and 0.67 (0.58-0.76)²⁷. Correspondingly, a secondary analysis of 958 women with hypovolemic shock due to postpartum hemorrhage in low-resource settings showed similar results for a composite maternal outcome for this cut-off value of ≥ 1.7 for the shock index, area under the curve of 0.76 (0.71-0.81). The composite outcome in this study consisted of maternal death, severe end-organ failure, intensive care unit admission, emergency hysterectomy and transfusion of ≥ 5 units of packed red blood cells²⁸.

Early warning scoring systems were also introduced to improve early recognition

of life threatening conditions. These scores are repeatedly calculated based on physiological parameters: heart rate, systolic blood pressure, respiratory rate, temperature and mental state ²⁹. The principle is that acute deterioration is preceded by subtle changes in these physiological parameters, and that these would be noticed earlier using *early warning scoring systems* than waiting for obvious changes in individual parameters ^{29,30}. In a systematic review, *early warning systems* were shown to successfully predict mortality in non-pregnant patients in different clinical settings ³¹. Another systematic review focused on critically ill patients and concluded that the use of many different *early warning score systems* with different trigger thresholds hampered meta-analysis of conflicting findings ³⁰.

Studies on the use of early warning systems in obstetric populations generally focus on several severe conditions in pregnancy and puerperium simultaneously, including preeclampsia, postpartum hemorrhage and sepsis. A retrospective study among 702 obstetric patients, in a low-resource setting, admitted to the intensive care unit showed an area under the curve for maternal death for high early warning scores of 0.84 (0.75-0.92) ³². Similarly, several other obstetric early warning systems also showed to be able to differentiate well between women with and without an adverse outcome ³³⁻³⁶. Maternal outcomes were also reported to improve after introduction of a Maternal Early Warning Trigger tool, as compared to before introduction of the tool. In this study, hysterectomy rates decreased from 0.94/1000 to 0.63/1000 deliveries ³⁷.

To conclude, adding *refractoriness to initial measures* to definitions of severe postpartum hemorrhage may warrant early identification of women at high risk of adverse outcome. Clinical tools as *shock index* and *early warning scores* seem to have a good ability to predict adverse outcomes in women with postpartum hemorrhage. Further studies to quantify the added clinical value with respect to preventing adverse outcomes are to be awaited.

Improving maternal outcomes: obstetric interventions to stop bleeding

Initial measures to stop bleeding depend on the primary cause of hemorrhage. In case of uterine atony, the uterus is massaged as soon as uterine atony is diagnosed, and uterotonic agents are administered. The first-choice uterotonic agent is oxytocin, but if unavailable, misoprostol or ergot alkaloids are recommended ^{12,38}. If postpartum hemorrhage occurs with the placenta still in utero, manual removal of the placenta is performed. If the placenta has already been delivered, examination of the uterine

cavity under anesthesia to exclude placental remnants should be considered. However, when postpartum hemorrhage proves to be refractory to these initial measures to stop bleeding, guidelines prostaglandins as second-line uterotonic agents for treatment of uterine atony^{16,18,39}. Bimanual uterine compression is recommended as a temporizing measure awaiting definitive uterotonic, surgical or radiological interventions to stop bleeding¹². Surgical and radiological interventions to stop bleeding include intrauterine balloon tamponade, arterial embolization, arterial ligation and uterine compression sutures (brace sutures). If bleeding persists despite these interventions, hysterectomy should be performed.

Hysterectomy to avoid maternal death should be performed “sooner rather than later”, according to the Royal College of Obstetricians & Gynaecologists (RCOG)¹⁶. Intrauterine balloon tamponade, arterial embolization, arterial ligation and uterine compression sutures have all been reported to be effective in stopping hemorrhage and preventing hysterectomy⁴⁰⁻⁵¹. Yet, if unsuccessful, these interventions may also delay hysterectomy, especially because they are performed with low frequency, and thus, experience with these techniques may be insufficient.

When it comes to these interventions to avoid hysterectomy in women with severe postpartum hemorrhage two important issues on the appropriate timing of hysterectomy need to be resolved. First, we need to be able to recognize situations in which hysterectomy will be needed anyway. If surgical and radiological interventions fail most of the time in women with already high volumes of blood loss, high bleeding rates or who are hemodynamically unstable at moment of employment of these interventions, perhaps treating physicians should immediately perform the hysterectomy⁵²⁻⁵⁴.

Second, we would argue for more insight into the interaction between the timing of the surgical and radiological and interventions and their success rates. Early employment of these interventions could minimize delay in hysterectomy in women in whom the bleeding proves refractory to these interventions. A study among 420 women with estimated blood loss >500 mL after vaginal delivery and >1000 mL after cesarean delivery assessed the effect of timing of uterine balloon tamponade and uterine artery embolization on maternal morbidity including hysterectomy and intensive care unit admission⁵⁵. Timing of intervention was expressed as a function of estimated blood loss at the moment of employment of the intervention, and early timing of balloon tamponade (n=48) was associated with improved maternal

outcomes. For early timing of arterial embolization (n=20), this association was not shown. Larger studies are needed to know whether these findings are robust, and whether earlier surgical and radiological interventions to stop bleeding result in a reduction in adverse maternal outcomes.

In conclusion, a better understanding of the influence of patient and bleeding characteristics and timing of interventions on the success rates of surgical and radiological interventions to stop bleeding is necessary to improve outcomes of women with postpartum hemorrhage.

Improving maternal outcomes: timing of switch from resuscitation with clear fluids to transfusion of blood products

Fluid resuscitation should start as soon as the severity of postpartum hemorrhage becomes evident, to maintain circulating blood volume and preserve tissue oxygenation⁸. The first stage of fluid resuscitation consists of administration of crystalloids and colloids, and in case of ongoing hemorrhage, this stage is followed by the second stage consisting of transfusion of blood products.

In addition to abovementioned goals of resuscitation, blood products are also administered to support hemostasis and correct coagulopathy. Transfusion of plasma provides deficient coagulation factors, and packed red blood cells may also support primary hemostasis through different mechanisms. Red blood cells in the center of the vessel lumen may increase platelet concentrations near the endothelium⁵⁶. Theoretically this so-called margination of platelets might support primary hemostasis, but this has not been supported by quantitative evidence. In addition, red blood cells may enhance platelet reactivity^{57,58}, support shear-induced platelet aggregation⁵⁹ and support thrombin generation by exposing procoagulant phospholipids⁶⁰⁻⁶².

Fluid resuscitation with high volumes of crystalloids and colloids, induces dilution of clotting factors and platelets, causing dilutional coagulopathy and thus aggravating hemorrhage⁶³. In women with severe postpartum hemorrhage it has never been assessed, nonetheless, which volumes of clear fluids cause dilutional coagulopathy, nor whether dilutional coagulopathy contributes to adverse maternal outcome. A study examining varying degrees of hemodilution in healthy volunteers showed both in vitro and in vivo that hemodilution with normal saline decreased concentrations of coagulation and antifibrinolytic factors (α 2-antiplasmin and thrombin-activatable fibrinolysis inhibitor (TAFI)), and decreased thrombin generation^{64,65}. Impaired

thrombin generation was also confirmed in bleeding patients with dilutional coagulopathy during major surgery, concomitant with impaired fibrin clot formation⁶⁶. In these patients, volume of crystalloids, colloids, but also red blood cells, exceeded 5L.

Moreover, colloid fluids have been associated with impairment of different aspects of coagulation. Colloid fluids like hydroxyethyl starches, dextrans and gelatins have been associated with impaired platelet function, inhibition of fibrin polymerization and increase of fibrinolysis, and may lead to decreased levels of von Willebrand factor^{65,67}. Clinically relevant effects of colloid fluids on coagulation in non-pregnant patients seem to arise when larger volumes are administered⁶⁷. Effects of administration of colloid fluids on adverse maternal outcome in women with postpartum hemorrhage are unknown.

The RCOG guideline on prevention and management of postpartum hemorrhage recommends a maximum volume of clear fluids of 3.5L before start of blood transfusion, comprising up to 2L crystalloids and 1.5L colloids¹⁶. This advice was based on consensus from a Working Party of Haemostasis and Thrombosis Task Force⁶⁸. However, thus far there is insufficient quantitative evidence to support this hypothesis. As a consequence, it is uncertain which volumes and combination of clear fluids increase the risk of adverse maternal outcome in women with postpartum hemorrhage.

Summarizing, resuscitation with clear fluids in women with postpartum hemorrhage is generally unavoidable because of the unpredictability of postpartum hemorrhage. However, switching to transfusion of blood products when these are available would probably reinforce hemostasis and thus be beneficial for women with ongoing postpartum hemorrhage.

Improving maternal outcomes: timing of hemostatic interventions to correct coagulopathy

Diagnosis of coagulopathy in women with postpartum hemorrhage

Pregnancy is a hypercoagulable state due to changes in the coagulation system throughout the pregnancy (figure 2)⁶⁹⁻⁷². The majority of procoagulant factors increase, while the level of protein S as endogenous anticoagulant and fibrinolytic activity decrease. The most marked increases in procoagulants seem to occur in

concentrations of factor VII, factor VIII, von Willebrand factor and fibrinogen ⁷². Fibrinogen concentration increases to approximately twice the non-pregnant values at term, with levels between 4 and 6 g/L ⁷¹. The physiologic increase in plasma volume in pregnancy may also cause a mild thrombocytopenia ⁷³. Altogether, haemostatic changes of pregnancy lead to a slightly shortened prothrombin time (PT) and activated partial thromboplastin time (APTT), within the range of non-pregnant reference values ^{69,71,73}.

A woman with ongoing postpartum hemorrhage may develop coagulopathy due to loss, dilution and consumption of platelets and clotting factors. All factors involved in coagulation may become deficient, procoagulant and anti-coagulant proteins, as well as fibrinolytic and antifibrinolytic proteins ⁶⁶. Impairment of hemostasis may also occur because of disseminated intravascular coagulation ⁶⁴. Risk factors for developing disseminated intravascular coagulation are placental abruption, preeclampsia with HELLP syndrome, and amniotic fluid embolism ⁶⁴.

The monitoring of coagulation in women with severe postpartum hemorrhage is subject of debate. Conventional hemostasis assays such as the PT and APTT tests are considered unsuitable because of an inability to detect specific changes in coagulation, a disregard of large parts of coagulation (i.e. platelet function and fibrinolysis) and long turn-around times ⁷⁴. Studies that assessed the changes in PT and APTT during postpartum hemorrhage reported values within non-pregnant reference values during postpartum hemorrhage, even with high volumes of blood loss ^{75,76}. Among 356 women with postpartum hemorrhage PT and aPTT measured at 1-1.5L blood loss were not associated with progression to blood loss >2.5L ⁷⁷.

Data on changes in platelet counts and function during postpartum hemorrhage are scarce. Available studies report minimal decreases of platelet counts during postpartum hemorrhage, and platelet counts measured in women with blood loss between 1 and 1.5L seem not to be associated with progression to higher volumes of blood loss ^{78,79}.

Several observational studies reported a plasma fibrinogen level measured early during postpartum hemorrhage to be predictive of progression to more severe bleeding and invasive procedures in women with postpartum hemorrhage ^{75,77,79-81}. Positive predictive value of a fibrinogen level ≤ 2 g/L for progression to severe bleeding was reported to be 100%, whilst negative predictive value of fibrinogen >4 g/L was 79%

⁷⁹. Reported odds ratios for fibrinogen <2 g/L for progression to severe hemorrhage were 12.0 (95% confidence interval 2.6-56.1) and for fibrinogen between 2 and 3 g/L 1.9 (1.2-3.1) ⁸⁰. A point-of-care test to measure fibrinogen within a few minutes or seconds might be a promising monitoring tool for women with severe postpartum hemorrhage.

Since obtaining results of standard coagulation screens are time-consuming, coagulation monitoring with point-of-care tests is increasingly used in women with severe postpartum hemorrhage to detect coagulopathy and guide hemostatic interventions. However, the clinical usefulness of thromboelastography and thromboelastometry in women with postpartum hemorrhage has not been established ⁷⁴. As with the standard coagulation screens, thromboelastography and thromboelastometry values are different from the non-pregnant population due to the prohemostatic changes of pregnancy ^{63,74}. Several observational studies reported reference values for these point-of-care tests in pregnancy and the peripartum period, confirming the increased coagulability with faster initiation of coagulation and decreased fibrinolysis ⁸²⁻⁸⁴. The next steps to be undertaken to eventually determine the clinical usefulness of these point-of-care tests in women with postpartum hemorrhage are 1) investigation of the changes in the measured values during postpartum hemorrhage and whether these measured values reflect impaired coagulation, as compared with standard coagulation assays, 2) investigation of appropriate interventions to correct these changes and 3) investigation of effects of the use of these tests in treatment algorithms for postpartum hemorrhage on clinically relevant maternal outcomes ⁸⁵.

Overall, there seem to be minimal changes in PT, aPTT and platelet counts during postpartum hemorrhage, and only low plasma fibrinogen concentrations seem associated with progression to larger bleeds. Clinical usefulness of thromboelastography and thromboelastometry in women with postpartum hemorrhage is yet to be determined.

Correction of coagulopathy: early timing of fresh frozen plasma

Early timing of fresh frozen plasma, expressed as a high fresh frozen plasma to packed red blood cells ratio, seemed to reduce mortality in (non-pregnant) trauma patients in observational studies. Despite concerns about high risk of bias in these studies, massive transfusion protocols incorporating high ratio plasma and platelets to red blood cells were widely implemented in many different clinical settings with major

hemorrhage. A randomized clinical trial among 680 trauma patients with major bleeding receiving either a plasma:platelets:red blood cells ratio of 1:1:1 or ratio 1:1:2 showed no statistically significant difference in 24 hours and 30 days mortality with risk differences -4.2% (95% confidence interval -9.6 to 1.1) and -3.7% (-10.2 to 2.7)⁸⁶. Death from exsanguination, a secondary outcome, was significantly decreased in patients that received a high ratio as compared with a low ratio, difference -5.4% (-10.4 tot -0.5).

In women with postpartum hemorrhage, studies on early timing of plasma to correct coagulopathy and improve maternal outcomes are limited. An observational before-and-after study among 142 women with severe postpartum hemorrhage, defined as postpartum hemorrhage requiring the second-line prostaglandin analogue sulprostone and packed red blood cells transfusion within six hours following delivery, compared fresh frozen plasma to red blood cells ratio of >0.5 with ratio ≤0.5 on advanced interventional procedures⁸⁷. To account for confounding by indication, propensity score matching was performed for the 41 women who received plasma. In this study, a low fresh frozen plasma to red blood cells ratio was associated with more advanced interventions, odds ratio 1.3 (1.1-1.5), suggesting a beneficial effect of administering plasma early during the course of postpartum hemorrhage⁸⁷.

High ratios of plasma to red blood cells in women with postpartum hemorrhage were also studied within massive transfusion protocols. These massive transfusion packs were part of an obstetric hemorrhage protocol that included a whole series of other changes in management¹¹. The combination of changes in management seemed to reduce blood product use in these women, but the ratios of blood products in the designated “obstetrics hemorrhage pack” were based on evidence from trauma-related hemorrhage. Future studies need to address the comparison of different transfusion protocols for postpartum hemorrhage.

Interestingly, in a recent observational study among 605 women with postpartum hemorrhage exceeding 1L of blood loss fresh frozen plasma was administered when thromboelastometry showed signs of fibrinogen deficiency (Fibtem A5 ≤15 mm)⁸⁸. The women who did not reach Fibtem A5 below 15 mm did not develop clinically significant hemostatic impairment, defined as continued bleeding and laboratory hemostatic failure (PT or aPTT >1.5 times the midpoint of the normal range or fibrinogen <2 g/L).

Concluding, whether early administration of plasma during the course of

postpartum hemorrhage improves maternal outcomes is still unclear.

Correction of coagulopathy: early timing of tranexamic acid

The effect of early administration of the antifibrinolytic agent tranexamic acid on maternal mortality and hysterectomy, as compared with placebo, has recently been assessed in the WOMAN trial, an international randomized controlled trial among 20060 women with postpartum hemorrhage ⁸⁹. Postpartum hemorrhage was defined as 500 or 1000 mL depending on the mode of delivery, or blood loss causing hemodynamic instability. In this study all-cause mortality and composite outcome consisting of all-cause mortality and hysterectomy did not differ between women treated with tranexamic acid or placebo, corresponding risk ratios 1.02 (0.88-1.07) and 0.97 (0.87-1.09). Compared with placebo, death due to bleeding was significantly reduced in women treated with tranexamic acid, risk ratio 0.81 (0.65-1.00), and when administered within three hours following birth 0.69 (0.52-0.91). Importantly, administration of tranexamic acid was not associated with an increased risk of venous thromboembolism.

Generalizability of the results of the WOMAN trial has been questioned, as almost all study participants (97%) were recruited in low-resource settings with high maternal mortality ratios ⁹⁰⁻⁹². Effect of adding tranexamic acid to treatment algorithms in high-resource settings, with advanced uterotonic, surgical and radiological interventions and transfusion of blood products available, on severe maternal morbidity and mortality remains unclear. A randomized controlled trial in a high-resource setting among 144 women with postpartum hemorrhage >800 mL following delivery compared the effect of high-dose tranexamic acid versus no tranexamic acid at moment of diagnosis of postpartum hemorrhage on total blood loss and invasive interventions to stop bleeding ⁹³. Tranexamic acid reduced median additional blood loss from moment of diagnosis of postpartum hemorrhage till end of bleeding slightly from 221 (interquartile range 105 to 564) to 173 mL (59 to 377) (p-value 0.04), and there was no difference in advanced interventions to stop bleeding. Similarly, a before-and-after observational study in a high-resource setting including 289 women with hemorrhage ≥500 mL following delivery, did not show a decrease in mean estimated blood loss after incorporating tranexamic acid in the treatment algorithm ⁹⁴. Additionally, early administration of tranexamic acid did not reduce adverse maternal outcome in a cohort study among 1260 women in the Netherlands with postpartum hemorrhage >1L and refractory to first-line obstetric interventions, odds ratio 0.9 (95% confidence interval 0.7-1.3) ⁹⁵.

In women with postpartum hemorrhage, early tranexamic acid seems to reduce the risk of maternal death due to exsanguination, with a favorable safety profile. However, the effect on maternal outcome in women with postpartum hemorrhage in high-resource settings may be limited. Future studies need to establish whether and when tranexamic acid improves clinical outcomes of women with postpartum hemorrhage.

Correction of coagulopathy: early timing of fibrinogen concentrate

Two randomized controlled trials investigated the effect of fibrinogen concentrate on maternal outcome. In the first trial, including 249 women with severe postpartum hemorrhage (after vaginal delivery >0.5L blood loss with retained placenta or >1L blood loss and intended manual exploration of the uterus, or >1L blood loss after caesarean delivery), pre-emptive treatment with 2g fibrinogen concentrate did not reduce the need for packed red blood cell transfusion or secondary outcomes, as compared with placebo ⁹⁶. At inclusion mean blood loss was 1459 mL (standard deviation 476 mL) and mean plasma fibrinogen level was 4.5 g/L (standard deviation 1.2). In the second trial, that randomized 55 women to fibrinogen concentrate or placebo, fibrinogen concentrate was administered in case the Fibtet A5-value, the thromboelastometry surrogate measure of plasma fibrinogen level, was below 15 mm ⁹⁷. This cut-off value for Fibtet was chosen after a preceding observational study among 365 women with postpartum hemorrhage (1-1.5L) indicating a predictive role of low Fibtet values for development of severe hemorrhage ⁷⁷. Median blood loss at time of study medication infusion was 1950 mL (interquartile range 1500-2285) and median fibrinogen level 2.5 g/L. In this trial administration of fibrinogen concentrate did not reduce the number of transfused blood components.

There are some published data on the use of algorithms to guide treatment of postpartum hemorrhage using thromboelastography and thromboelastometry. A before-and-after observational study with Rotem-guided fibrinogen concentrate administration reported a lower blood components use as compared with administration of fresh frozen plasma in major hemorrhage transfusion packs ⁹⁸. The study included 93 women with ongoing postpartum hemorrhage (>1500 mL) and coagulopathy defined as Fibtet A5 <12mm.

Thus, administration of fibrinogen concentrate to women with ongoing postpartum hemorrhage and fibrinogen level above 2g/L does not seem associated with better

maternal outcomes. Trials with fibrinogen administration in women with postpartum hemorrhage and plasma fibrinogen levels below 2g/L might demonstrate an effect on maternal outcomes. Before performing these trials, we need a test that provides fast and accurate estimates of a woman's fibrinogen concentration.

Correction of coagulopathy: recombinant activated factor VII

Following an abundance of case series, only one randomized controlled trial has been published on administration of recombinant activated factor VII in women with postpartum hemorrhage for correction of coagulopathy ⁹⁹. In this open-label trial 84 women with severe postpartum hemorrhage (>1.5L) refractory to the uterotonic agent sulprostone were randomized to a single dose of recombinant activated factor VII (60 ug/kg) or standard care. Randomization occurred one hour after onset of sulprostone, and outcomes were the need of advanced surgical or radiological intervention after randomization. Early administration of recombinant factor VII was associated with a reduction in advanced interventions to stop bleeding, relative risk 0.56 (0.42-0.76). However, information bias could have influenced the study results, as there was no allocation concealment in the study. Venous thromboembolism occurred in 5% of women who received recombinant activated factor VII, and did not occur in the women who underwent standard care. In a meta-analysis including only randomized controlled trials among non-obstetric bleeding patients this hemostatic agent was associated with arterial thromboembolism with odds ratio 1.7 (1.2-2.4), but not with venous thromboembolism (odds ratio 0.9 (0.7-1.2)) ¹⁰⁰.

Correction of coagulopathy: prothrombin complex concentrate

To date, comparative studies on administration of prothrombin complex concentrate in women with postpartum hemorrhage have not been published. A randomized controlled trial comparing prothrombin complex concentrate and fibrinogen concentrate with fresh frozen plasma (NCT01910675) did not get permission from the appropriate Medical Ethical Committee, because it was not feasible to get proper informed consent from these acute, severely ill patients (personal communication).

Conclusion

In the optimization of management of postpartum hemorrhage we are still facing several challenges. Early recognition of women at high risk of adverse outcomes because of postpartum hemorrhage may be achieved by adaptations to the definition of severe postpartum hemorrhage and the use of clinical tools such as *shock index* and

early warning scores.

Optimization of timing of surgical, radiological and hemostatic interventions in these women to stop bleeding and timing of switch from resuscitation with clear fluids to transfusion of blood products is of utmost importance to reach the goal of improving maternal outcomes. However, well-designed studies on obstetric interventions to stop bleeding are scarce and results from studies on hemostatic interventions to stop hemorrhage in these women show conflicting results. Broadening our understanding of the interaction of individual patient characteristics with these interventions will enable us to improve management and outcomes of women with severe postpartum hemorrhage.

Addendum

D.D.C.A. Henriquez collected literature and wrote the first draft of the manuscript. All authors were involved in interpretation of data and revision of the manuscript.

Acknowledgements

We thank L.M. de Looij for his help with language editing and the JTH reviewers for their helpful comments to improve our manuscript.

References

1. Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. *The Lancet Global health* 2014;2:e323-33.
2. Callaghan WM, Kuklina EV, Berg CJ. Trends in postpartum hemorrhage: United States, 1994-2006. *American journal of obstetrics and gynecology* 2010;202:353.e1-6.
3. Ford JB, Patterson JA, Seeho SK, Roberts CL. Trends and outcomes of postpartum haemorrhage, 2003-2011. *BMC pregnancy and childbirth* 2015;15:334.
4. Knight M, Callaghan WM, Berg C, et al. Trends in postpartum hemorrhage in high resource countries: a review and recommendations from the International Postpartum Hemorrhage Collaborative Group. *BMC pregnancy and childbirth* 2009;9:55.
5. Mehrabadi A, Liu S, Bartholomew S, et al. Temporal trends in postpartum hemorrhage and severe postpartum hemorrhage in Canada from 2003 to 2010. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC* 2014;36:21-33.
6. van Stralen G, von Schmidt Auf Altenstadt JF, Bloemenkamp KW, van Roosmalen J, Hukkelhoven CW. Increasing incidence of postpartum hemorrhage: the Dutch piece of the puzzle. *Acta obstetrica et gynecologica Scandinavica* 2016;95:1104-10.
7. Kramer MS, Berg C, Abenhaim H, et al. Incidence, risk factors, and temporal trends in severe postpartum hemorrhage. *American journal of obstetrics and gynecology* 2013;209:449.e1-7.
8. Abdul-Kadir R, McLintock C, Ducloy AS, et al. Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. *Transfusion* 2014;54:1756-68.
9. Arora KS, Shields LE, Grobman WA, D'Alton ME, Lappen JR, Mercer BM. Triggers, bundles, protocols, and checklists--what every maternal care provider needs to know. *American journal of obstetrics and gynecology* 2016;214:444-51.
10. Einerson BD, Miller ES, Grobman WA. Does a postpartum hemorrhage patient safety program result in sustained changes in management and outcomes? *American journal of obstetrics and gynecology* 2015;212:140-4.e1.
11. Shields LE, Wiesner S, Fulton J, Pelletreau B. Comprehensive maternal hemorrhage protocols reduce the use of blood products and improve patient safety. *American journal of obstetrics and gynecology* 2015;212:272-80.
12. WHO recommendations for the prevention and treatment of postpartum haemorrhage. 2012. (Accessed 1 October 2017, at http://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf.)
13. Dahlke JD, Mendez-Figueroa H, Maggio L, et al. Prevention and management of postpartum hemorrhage: a comparison of 4 national guidelines. *American journal of obstetrics and gynecology* 2015;213:76.e1-10.
14. Schaap T, Bloemenkamp K, Deneux-Tharaux C, et al. Defining definitions: a Delphi study to develop a core outcome set for conditions of severe maternal morbidity. *BJOG : an international journal of obstetrics and gynaecology* 2017.
15. Hancock A, Weeks AD, Lavender DT. Is accurate and reliable blood loss estimation the 'crucial step' in early detection of postpartum haemorrhage: an integrative review of the literature. *BMC pregnancy and childbirth* 2015;15:230.
16. Postpartum haemorrhage, prevention and management (Green-top guideline no. 52). 2016. (Accessed 1 October 2017, at <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg52/>.)
17. Leduc D, Senikas V, Lalonde AB, et al. Active management of the third stage of labour: prevention and treatment of postpartum hemorrhage. *Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC* 2009;31:980-93.
18. Sentilhes L, Vayssi re C, Deneux-Tharaux C, et al. Postpartum hemorrhage: guidelines for clinical practice from the French

College of Gynaecologists and Obstetricians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR). European journal of obstetrics, gynecology, and reproductive biology 2016;198:12-21.

19. Reimold SC, Rutherford JD. Clinical practice. Valvular heart disease in pregnancy. The New England journal of medicine 2003;349:52-9.
20. Windram JD, Colman JM, Wald RM, Udell JA, Siu SC, Silversides CK. Valvular heart disease in pregnancy. Best practice & research Clinical obstetrics & gynaecology 2014;28:507-18.
21. Pacagnella RC, Souza JP, Durocher J, et al. A systematic review of the relationship between blood loss and clinical signs. PloS one 2013;8:e57594.
22. Lai WH, Wu SC, Rau CS, et al. Systolic Blood Pressure Lower than Heart Rate upon Arrival at and Departure from the Emergency Department Indicates a Poor Outcome for Adult Trauma Patients. International journal of environmental research and public health 2016;13.
23. Pandit V, Rhee P, Hashmi A, et al. Shock index predicts mortality in geriatric trauma patients: an analysis of the National Trauma Data Bank. The journal of trauma and acute care surgery 2014;76:1111-5.
24. Rousseaux J, Grandbastien B, Dorkenoo A, Lampin ME, Leteurtre S, Leclerc F. Prognostic value of shock index in children with septic shock. Pediatric emergency care 2013;29:1055-9.
25. Spyridopoulos I, Noman A, Ahmed JM, et al. Shock-index as a novel predictor of long-term outcome following primary percutaneous coronary intervention. European heart journal Acute cardiovascular care 2015;4:270-7.
26. Taylor D, Fleischer A, Meirowitz N, Rosen L. Shock index and vital-sign reference ranges during the immediate postpartum period. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2017;137:192-5.
27. Nathan HL, El Ayadi A, Hezelgrave NL, et al. Shock index: an effective predictor of outcome in postpartum haemorrhage? BJOG : an international journal of obstetrics and gynaecology

2015;122:268-75.

28. El Ayadi AM, Nathan HL, Seed PT, et al. Vital Sign Prediction of Adverse Maternal Outcomes in Women with Hypovolemic Shock: The Role of Shock Index. PloS one 2016;11:e0148729.
29. The Confidential Enquiry into Maternal and Child Health (CEMACH). Saving Mothers Lives; reviewing maternal deaths to make motherhood safer 2003–05. The Seventh Report of the United Kingdom Confidential Enquiries into Maternal Deaths in the United Kingdom. CEMACH, 2007. (Accessed 2 October 2017., at <http://www.cmacce.org.uk/>.)
30. Alam N, Hobbelink EL, van Tienhoven AJ, van de Ven PM, Jansma EP, Nanayakkara PW. The impact of the use of the Early Warning Score (EWS) on patient outcomes: a systematic review. Resuscitation 2014;85:587-94.
31. Smith ME, Chiovaro JC, O'Neil M, et al. Early warning system scores for clinical deterioration in hospitalized patients: a systematic review. Annals of the American Thoracic Society 2014;11:1454-65.
32. Paternina-Caicedo A, Miranda J, Bourjeily G, et al. Performance of the Obstetric Early Warning Score in critically ill patients for the prediction of maternal death. American journal of obstetrics and gynecology 2017;216:58.e1-.e8.
33. Carle C, Alexander P, Columb M, Johal J. Design and internal validation of an obstetric early warning score: secondary analysis of the Intensive Care National Audit and Research Centre Case Mix Programme database. Anaesthesia 2013;68:354-67.
34. Hedriana HL, Wiesner S, Downs BG, Pelletreau B, Shields LE. Baseline assessment of a hospital-specific early warning trigger system for reducing maternal morbidity. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 2016;132:337-41.
35. Singh A, Guleria K, Vaid NB, Jain S. Evaluation of maternal early obstetric warning system (MEOWS chart) as a predictor of obstetric morbidity: a prospective observational study. European journal of obstetrics, gynecology, and reproductive biology 2016;207:11-7.

36. Singh S, McGlennan A, England A, Simons R. A validation study of the CEMACH recommended modified early obstetric warning system (MEOWS). *Anaesthesia* 2012;67:12-8.
37. Shields LE, Wiesner S, Klein C, Pelletreau B, Hedriana HL. Use of Maternal Early Warning Trigger tool reduces maternal morbidity. *American journal of obstetrics and gynecology* 2016;214:527.e1-6.
38. Mousa HA, Blum J, Abou El Senoun G, Shakur H, Alfirevic Z. Treatment for primary postpartum haemorrhage. *The Cochrane database of systematic reviews* 2014:Cd003249.
39. NVOG-richtlijn Hemorrhagia postpartum (HPP). 2015. (Accessed 1 October 2017, at <http://nvog-documenten.nl/uploaded/docs/NVOG%20richtlijn%20HPP%2014-11-2013%20herzien%202015lhe.pdf>.)
40. Aderoba AK, Olagbuji BN, Akintan AL, Oyeneyin OL, Owa OO, Osaikhuwuomwan JA. Condom-catheter tamponade for the treatment of postpartum haemorrhage and factors associated with success: a prospective observational study. *BJOG : an international journal of obstetrics and gynaecology* 2017;124:1764-71.
41. Chan LL, Lo TK, Lau WL, et al. Use of second-line therapies for management of massive primary postpartum hemorrhage. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics* 2013;122:238-43.
42. Cheong JY, Kong TW, Son JH, Won JH, Yang JJ, Kim HS. Outcome of pelvic arterial embolization for postpartum hemorrhage: A retrospective review of 117 cases. *Obstetrics & gynecology science* 2014;57:17-27.
43. Gauchotte E, De La Torre M, Perdrille-Galet E, Lamy C, Gauchotte G, Morel O. Impact of uterine balloon tamponade on the use of invasive procedures in severe postpartum hemorrhage. *Acta obstetrica et gynecologica Scandinavica* 2017;96:877-82.
44. Kayem G, Kurinczuk JJ, Alfirevic Z, Spark P, Brocklehurst P, Knight M. Specific second-line therapies for postpartum haemorrhage: a national cohort study. *BJOG : an international journal of obstetrics and gynaecology* 2011;118:856-64.
45. Lee HY, Shin JH, Kim J, et al. Primary postpartum hemorrhage: outcome of pelvic arterial embolization in 251 patients at a single institution. *Radiology* 2012;264:903-9.
46. Lo A, St Marie P, Yadav P, Belisle E, Markenson G. The impact of Bakri balloon tamponade on the rate of postpartum hysterectomy for uterine atony. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2017;30:1163-6.
47. Martin E, Legendre G, Bouet PE, Cheve MT, Multon O, Sentilhes L. Maternal outcomes after uterine balloon tamponade for postpartum hemorrhage. *Acta obstetrica et gynecologica Scandinavica* 2015;94:399-404.
48. Revert M, Cottenet J, Raynal P, Cibot E, Quantin C, Rozenberg P. Intrauterine balloon tamponade for management of severe postpartum haemorrhage in a perinatal network: a prospective cohort study. *BJOG : an international journal of obstetrics and gynaecology* 2017;124:1255-62.
49. Sentilhes L, Gromez A, Clavier E, Resch B, Verspyck E, Marpeau L. Predictors of failed pelvic arterial embolization for severe postpartum hemorrhage. *Obstetrics and gynecology* 2009;113:992-9.
50. Touboul C, Badiou W, Saada J, et al. Efficacy of selective arterial embolisation for the treatment of life-threatening post-partum haemorrhage in a large population. *PloS one* 2008;3:e3819.
51. Vintejoux E, Ulrich D, Mousty E, et al. Success factors for Bakri balloon usage secondary to uterine atony: a retrospective, multicentre study. *The Australian & New Zealand journal of obstetrics & gynaecology* 2015;55:572-7.
52. Knight M, Seeney FM, Hopkinson C, et al. Authors' reply re: The epidemiology and outcomes of women with postpartum haemorrhage requiring massive transfusion with eight or more units of red cells: a national cross-sectional study. *BJOG : an international journal of obstetrics and gynaecology* 2017;124:167-8.
53. Matsubara S, Takahashi H, Baba Y,

- Lefor AK. Re: Intrauterine balloon tamponade for management of severe postpartum haemorrhage in a perinatal network: a prospective cohort study: Exclusion criteria? BJOG : an international journal of obstetrics and gynaecology 2017;124:1792-3.
54. Rozenberg P, Revert M. Authors' reply re: Intrauterine balloon tamponade for management of severe postpartum haemorrhage in a perinatal network: a prospective cohort study. BJOG : an international journal of obstetrics and gynaecology 2017;124:1793-4.
55. Howard TF, Grobman WA. The relationship between timing of postpartum hemorrhage interventions and adverse outcomes. American journal of obstetrics and gynecology 2015;213:239.e1-3.
56. Aarts PA, van den Broek SA, Prins GW, Kuiken GD, Sixma JJ, Heethaar RM. Blood platelets are concentrated near the wall and red blood cells, in the center in flowing blood. Arteriosclerosis (Dallas, Tex) 1988;8:819-24.
57. Santos MT, Valles J, Marcus AJ, et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. The Journal of clinical investigation 1991;87:571-80.
58. Valles J, Santos MT, Aznar J, et al. Erythrocytes metabolically enhance collagen-induced platelet responsiveness via increased thromboxane production, adenosine diphosphate release, and recruitment. Blood 1991;78:154-62.
59. Reimers RC, Sutura SP, Joist JH. Potentiation by red blood cells of shear-induced platelet aggregation: relative importance of chemical and physical mechanisms. Blood 1984;64:1200-6.
60. Litvinov RI, Weisel JW. Role of red blood cells in haemostasis and thrombosis. ISBT science series 2017;12:176-83.
61. Peyrou V, Lormeau JC, Herault JP, Gaich C, Pflieger AM, Herbert JM. Contribution of erythrocytes to thrombin generation in whole blood. Thrombosis and haemostasis 1999;81:400-6.
62. Turitto VT, Weiss HJ. Red blood cells: their dual role in thrombus formation. Science (New York, NY) 1980;207:541-3.
63. Bonnet MP, Basso O. Prohemostatic interventions in obstetric hemorrhage. Seminars in thrombosis and hemostasis 2012;38:259-64.
64. Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA. Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. British journal of anaesthesia 2010;104:318-25.
65. Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010;113:1205-19.
66. Schols SE, Lance MD, Feijge MA, et al. Impaired thrombin generation and fibrin clot formation in patients with dilutional coagulopathy during major surgery. Thrombosis and haemostasis 2010;103:318-28.
67. Levi M, Jonge E. Clinical relevance of the effects of plasma expanders on coagulation. Seminars in thrombosis and hemostasis 2007;33:810-5.
68. Walker ID, Walker JJ, Colvin BT, Letsky EA, Rivers R, Stevens R. Investigation and management of haemorrhagic disorders in pregnancy. Haemostasis and Thrombosis Task Force. Journal of clinical pathology 1994;47:100-8.
69. Cerneca F, Ricci G, Simeone R, Malisano M, Alberico S, Guaschino S. Coagulation and fibrinolysis changes in normal pregnancy. Increased levels of procoagulants and reduced levels of inhibitors during pregnancy induce a hypercoagulable state, combined with a reactive fibrinolysis. European journal of obstetrics, gynecology, and reproductive biology 1997;73:31-6.
70. Solomon C, Collis RE, Collins PW. Haemostatic monitoring during postpartum haemorrhage and implications for management. British journal of anaesthesia 2012;109:851-63.
71. Szecsi PB, Jorgensen M, Klajnbard A, Andersen MR, Colov NP, Stender S. Haemostatic reference intervals in pregnancy. Thrombosis and haemostasis 2010;103:718-27.
72. Franchini M. Haemostasis and pregnancy.

Thrombosis and haemostasis 2006;95:401-13.

73. Allard S, Green L, Hunt BJ. How we manage the haematological aspects of major obstetric haemorrhage. *British journal of haematology* 2014;164:177-88.

74. Levi M, Hunt BJ. A critical appraisal of point-of-care coagulation testing in critically ill patients. *Journal of thrombosis and haemostasis : JTH* 2015;13:1960-7.

75. de Lloyd L, Bovington R, Kaye A, et al. Standard haemostatic tests following major obstetric haemorrhage. *International journal of obstetric anaesthesia* 2011;20:135-41.

76. Green L, Knight M, Seeney F, et al. The haematological features and transfusion management of women who required massive transfusion for major obstetric haemorrhage in the UK: a population based study. *British journal of haematology* 2016;172:616-24.

77. Collins PW, Lilley G, Bruynseels D, et al. Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. *Blood* 2014;124:1727-36.

78. Jones RM, de Lloyd L, Kealaher EJ, et al. Platelet count and transfusion requirements during moderate or severe postpartum haemorrhage. *Anaesthesia* 2016;71:648-56.

79. Charbit B, Mandelbrot L, Samain E, et al. The decrease of fibrinogen is an early predictor of the severity of postpartum hemorrhage. *Journal of thrombosis and haemostasis : JTH* 2007;5:266-73.

80. Cortet M, Deneux-Tharaux C, Dupont C, et al. Association between fibrinogen level and severity of postpartum haemorrhage: secondary analysis of a prospective trial. *British journal of anaesthesia* 2012;108:984-9.

81. Gayat E, Resche-Rigon M, Morel O, et al. Predictive factors of advanced interventional procedures in a multicentre severe postpartum haemorrhage study. *Intensive care medicine* 2011;37:1816-25.

82. de Lange NM, van Rhee-Flach LE, Lance MD, et al. Peri-partum reference ranges for ROTEM(R) thromboelastometry. *British journal of anaesthesia* 2014;112:852-9.

83. Karlsson O, Sporrang T, Hillarp A, Jeppsson A, Hellgren M. Prospective longitudinal study of thromboelastography and standard hemostatic laboratory tests in healthy women during normal pregnancy. *Anesthesia and analgesia* 2012;115:890-8.

84. Shreeve NE, Barry JA, Deutsch LR, Gomez K, Kadir RA. Changes in thromboelastography parameters in pregnancy, labor, and the immediate postpartum period. *International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics* 2016;134:290-3.

85. van der Bom JG. Rotem in postpartum hemorrhage. *Blood* 2014;124:1700-1.

86. Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *Jama* 2015;313:471-82.

87. Pasquier P, Gayat E, Rackelboom T, et al. An observational study of the fresh frozen plasma: red blood cell ratio in postpartum hemorrhage. *Anesthesia and analgesia* 2013;116:155-61.

88. Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometry guided fresh frozen plasma infusion for postpartum haemorrhage: OBS2, an observational study. *British journal of anaesthesia* 2017;119:422-34.

89. WOMAN_Trial_Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. *Lancet (London, England)* 2017;389:2105-16.

90. Chassard D, Bouvet L. Administration of tranexamic acid to reduce maternal mortality related to postpartum haemorrhage: comments on the WOMAN trial. *International journal of obstetric anaesthesia* 2017.

91. Ducloy-Bouthors AS, Godier A. Should we add tranexamic acid to postpartum haemorrhage protocols after the WOMAN trial publication? *Anaesthesia, critical care & pain medicine* 2017.

92. Pacheco LD, Hankins GDV, Saad AF, Costantine MM, Chiossi G, Saade GR.

Tranexamic Acid for the Management of Obstetric Hemorrhage. *Obstetrics and gynecology* 2017;130:765-9.

93. Ducloy-Bouthors AS, Jude B, Duhamel A, et al. High-dose tranexamic acid reduces blood loss in postpartum haemorrhage. *Critical care (London, England)* 2011;15:R117.

94. Bouet PE, Ruiz V, Legendre G, Gillard P, Descamps P, Sentilhes L. Policy of high-dose tranexamic acid for treating postpartum hemorrhage after vaginal delivery. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet* 2016;29:1617-22.

95. Gillissen A, Henriquez D, van den Akker T, et al. The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study. *PloS one* 2017;12:e0187555.

96. Wikkelsso AJ, Edwards HM, Afshari A, et al. Pre-emptive treatment with fibrinogen

concentrate for postpartum haemorrhage: randomized controlled trial. *British journal of anaesthesia* 2015;114:623-33.

97. Collins PW, Cannings-John R, Bruynseels D, et al. Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. *British journal of anaesthesia* 2017;119:411-21.

98. Mallaiah S, Barclay P, Harrod I, Chevannes C, Bhalla A. Introduction of an algorithm for ROTEM-guided fibrinogen concentrate administration in major obstetric haemorrhage. *Anaesthesia* 2015;70:166-75.

99. Lavigne-Lissalde G, Aya AG, Mercier FJ, et al. Recombinant human FVIIa for reducing the need for invasive second-line therapies in severe refractory postpartum hemorrhage: a multicenter, randomized, open controlled trial. *Journal of thrombosis and haemostasis : JTH* 2015;13:520-9.

100. Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. *The New England journal of medicine* 2010;363:1791-800.




Figure 2. Hemostatic changes during normal pregnancy. The overall increase in pro-coagulant factors results in a hypercoagulable state which increases throughout pregnancy. Increases and decreases are relative to non-pregnancy. Positioning of factors is not indicative of the precise level of increase or decrease. FV, Factor V; FVII, Factor VII; FVIII, Factor VIII; FIX, Factor IX; FX, Factor X; FXI, Factor XI; FXII, Factor XII; FXIII, Factor XIII; PAI-1, plasminogen activator inhibitor 1; TAFI, thrombin activatable fibrinolysis inhibitor; TAT complex, thrombin-antithrombin complex; tPA, tissue plasminogen activator; vWF, von Willebrand factor. Solomon et al. [70]